GlassScriptPhysician profile
Heather Berlin Richardson
NPI 1558822981
$9,579.60
in general payments reported to CMS, 2019-2025
22 companies · $1,693 in 2025
The $1,693 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,137 · 2022: $1,619 · 2023: $2,529 · 2024: $2,602 · 2025: $1,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,824.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,719.31 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,591.23 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,489.33 | 2021-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $648.40 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $638.78 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $606.35 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $509.97 | 2021-2024 | Trintellix |
| Lundbeck LLC | $386.14 | 2021-2025 | Rexulti |
| Corium, LLC | $369.84 | 2022-2024 | Azstarys |
| Tris Pharma INC | $304.88 | 2022-2025 | Dyanavel Xr |
| Alkermes, INC. | $248.66 | 2022-2024 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $222.82 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $177.53 | 2023-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $144.12 | 2022-2025 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $123.41 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $97.37 | 2023-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $95.46 | 2022-2024 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $71.19 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $58.18 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $33.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $29.73 | 2022-2025 | Austedo Xr |
| Adlon Therapeutics L.P. | $13.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.